预约演示
更新于：2025-05-07
Amisulpride
氨磺必利
更新于：2025-05-07
概要
基本信息
药物类型 小分子化药 |
别名 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide、4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide、Aminosultopride + [17] |
作用方式 拮抗剂 |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂)、D3 receptor拮抗剂(多巴胺D3受体拮抗剂) |
非在研适应症 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H27N3O4S |
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N |
CAS号71675-85-9 |
关联
105
项与 氨磺必利 相关的临床试验CTRI/2025/04/085584
A prospective study comparing the efficacy of amisulpride,palanosetron and ondansetron with dexamethasone for postoperative nausea and vomiting in patients coming for elective laparoscopic cholecystectomy under general anaesthesia-a randomised control trial - Nil
NCT06887621
Patients at High Risk for Postoperative Nausea and Vomiting Undergoing Gynecological Surgery: Efficacy of Oral Amisulpride in Combination With Intravenous Ondansetron and Dexamethasone - a Parallel-group Randomized Trial
CTRI/2024/11/077170
Comparison of Amisulpride vs Ondansetron in the prophylaxis of Post Operative Nausea and Vomiting in abdominal surgeries: a randomized controlled study. - NIL
100 项与 氨磺必利 相关的临床结果
登录后查看更多信息
100 项与 氨磺必利 相关的转化医学
登录后查看更多信息
100 项与 氨磺必利 相关的专利（医药）
登录后查看更多信息
2,312
项与 氨磺必利 相关的文献（医药）2025-06-01COMPUTERS IN BIOLOGY AND MEDICINE
Photodegradation of psychotropic medications: Impact on efficacy, safety, and drug properties
Article
作者: Staicu, Angela ; Udrea, Ana-Maria ; Avram, Speranta ; Dabu, Aurelia Nicoleta ; Buiu, Catalin
Antipsychotics and antidepressants are essential psychotropic medications used for treating various mental health conditions such as depression, schizophrenia, and bipolar disorder. However, when exposed to light, these compounds are susceptible to photodegradation, potentially changing their biological activity and safety profiles. This study evaluates the pharmacokinetic and pharmacodynamic properties of several photoproducts derived from 13 psychotropic drugs. We used computational methods to predict the biological activity, toxicity, and drug-like properties of the photoproducts. Our results indicate that photoproducts such as amisulpride_TP166, TP246, quetiapine_D4, and quetiapine_PH1 show enhanced biological affinity and ADME-Tox profiles similar to their parent compounds, suggesting possible therapeutic advantages in their interaction with targeted receptors. However, some of the photocompounds exhibit lower predicted binding affinities when interacting with those receptors compared to their parent compounds, indicating a possible loss of function. These findings emphasize the need for further investigation into the effects and safety of drug photoproducts, particularly in the context of long-term pharmacotherapy.
2025-06-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-associated hyperprolactinemia: A comprehensive disproportionality analysis based on the FAERS database
Article
作者: Zeng, Fanxiang ; Chen, Huajiao ; Zhang, Jinhua ; Zheng, Cuixian ; Liu, Jinhua ; Liu, Ying ; Xue, Liping ; Fang, Xinyi
Hyperprolactinemia (HPRL) is a clinically significant adverse event that requires careful monitoring. This study aims to identify the medications associated with HPRL using data from the FDA Adverse Event Reporting System (FAERS) between 2004Q1 and 2024Q1. Disproportionality analysis was performed to identify potential drug signals. Sensitivity analysis was conducted to assess the stability and strength of HPRL signals associated with these medications, as well as to examine signal differences by age and gender through stratification. Time-to-onset (TTO) analysis was performed to investigate the factors affecting the onset of HPRL. Disproportionality analyses identified 39 drugs related to HPRL across six main anatomical systems, with the majority (N = 29) affecting the nervous system. Notably, most of these medications belong to psychotropic categories, including atypical antipsychotics (AAPs, N = 13), typical antipsychotics (TAPs, N = 5) and selective serotonin reuptake inhibitors (SSRIs, N = 5). Sensitivity analysis indicated that most signals remained robust, with risperidone exhibiting the strongest signal for HPRL, followed by amisulpride, paliperidone, fluphenazine, and thioridazine. Stratified analysis showed that females had stronger signals for HPRL. Compared to individuals aged 18-44, those aged ≥45 exhibited weaker signals, while the signals in minors varied by drug. TTO analysis revealed that AAP-related HPRL manifested earlier in females, with earlier onset observed in minors using AAPs or SSRIs. In conclusion, we identified and ranked drugs associated with HPRL, primarily psychotropic medications, and observed variations in signal strength and onset time across gender and age. These findings emphasize the importance of individualized HPRL screening based on specific medications, gender, and age.
2025-05-01PHYSIOLOGY & BEHAVIOR
Therapeutic effects of amisulpride in male schizophrenics: Role of short-chain fatty acids and gene expression changes
Article
作者: Lin, Yichuan ; Fang, Hongqiao ; Ko, Chih-Yuan ; Zheng, Jinchi ; Weng, Saizheng
Schizophrenia (SCZ) is a complex disorder characterized by acute symptom exacerbations. Amisulpride, an antipsychotic, has shown effects beyond its primary neurochemical actions, suggesting an influence on the gut microbiome, cytokine modulation, and short-chain fatty acid (SCFA) metabolism. This study aims to investigate these broader effects by examining changes in serum SCFA levels and gene expression profiles in peripheral blood mononuclear cells (PBMCs) following amisulpride treatment. Patients with SCZ undergoing a four-week amisulpride regimen were enrolled. Serum SCFA levels were quantified by gas chromatography, and gene expression profiling was performed in PBMCs using real-time quantitative polymerase chain reaction to assess treatment-associated changes. Results revealed that treatment with amisulpride resulted in a significant increase in serum acetate levels. Gene expression analysis revealed upregulation of G-protein coupled receptor 109a (GPR109a), histone deacetylase 1 (HDAC1), G-protein coupled receptor 43 (GPR43), Toll-like receptor 2 (TLR2), soluble CD14 (sCD14), and N-methyl-d-aspartate receptor (NMDAR), while Toll-like receptor 4 (TLR4) and pregnane X receptor (PXR) were downregulated. These findings suggest that amisulpride may modulate acetate metabolism and immune signaling pathways in SCZ, potentially contributing to anti-inflammatory effects and neuroimmune regulation. The observed increase in acetate, a key microbial metabolite, and the altered expression of immune-related genes suggest a possible link between metabolic shifts and immunomodulatory responses in SCZ pathophysiology. However, direct evidence linking these changes to gut-brain axis mechanisms remains insufficient. Further research is needed to elucidate the therapeutic implications of these metabolic and immunological alterations and their potential role in symptom modulation.
100 项与 氨磺必利 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 术后恶心呕吐 | 美国 | 2020-02-26 | |
| 精神分裂症 | 中国 | 2004-06-04 | |
| 急性精神分裂症 | 澳大利亚 | 2002-02-01 | |
| 慢性精神分裂症 | 澳大利亚 | 2002-02-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心和呕吐 | 临床3期 | 中国 | 2023-01-12 | |
| 恶心 | 临床3期 | 美国 | 2015-09-01 | |
| 恶心 | 临床3期 | 法国 | 2015-09-01 | |
| 恶心 | 临床3期 | 德国 | 2015-09-01 | |
| 呕吐 | 临床3期 | 美国 | 2015-09-01 | |
| 呕吐 | 临床3期 | 法国 | 2015-09-01 | |
| 呕吐 | 临床3期 | 德国 | 2015-09-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 丹麦 | 2011-02-01 | |
| 化疗引起的恶心和呕吐 | 临床2期 | 英国 | 2011-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 60 | (Amisulpride Group) | 襯網獵壓願齋壓觸窪簾(淵醖糧鏇觸餘窪淵構遞) = 憲鏇壓製夢糧鑰窪獵觸 獵獵積憲鏇膚鹽壓獵膚 (鬱膚觸製顧糧鑰構觸顧, 0.47) 更多 | - | 2024-09-19 | |
Olanzapine-Fluoxetine Combination (Olanzapine-Fluoxetine Group) | 襯網獵壓願齋壓觸窪簾(淵醖糧鏇觸餘窪淵構遞) = 積鏇觸鑰繭鏇淵衊網觸 獵獵積憲鏇膚鹽壓獵膚 (鬱膚觸製顧糧鑰構觸顧, 0.60) 更多 | ||||||
Pubmed 人工标引  | N/A | 25 | 壓選壓鏇築選製夢鏇鬱(衊糧鏇膚窪鹽廠繭淵衊) = not statistically significant 範醖齋糧觸積壓鹽構憲 (夢憲夢選廠蓋廠鬱廠製 ) 更多 | 积极 | 2022-08-31 | ||
临床3期 | 465 | 齋膚夢顧鹹糧衊繭築蓋(構顧糧淵齋鬱繭衊選醖) = 遞製蓋蓋齋壓範顧構憲 積鬱襯憲窪鑰廠鹹艱鏇 (鹽膚鏇糧壓獵範蓋簾鹹 ) 更多 | 积极 | 2022-06-02 | |||
Placebo | 齋膚夢顧鹹糧衊繭築蓋(構顧糧淵齋鬱繭衊選醖) = 壓淵襯淵繭餘醖築壓鹽 積鬱襯憲窪鑰廠鹹艱鏇 (鹽膚鏇糧壓獵範蓋簾鹹 ) 更多 | ||||||
临床1期 | 30 | Amisulpride 10 mg | 積壓壓範鑰選選餘蓋窪(衊構顧繭窪夢築蓋齋顧) = 壓憲積蓋蓋範鏇壓糧構 網鹽蓋繭願醖顧選憲願 (鹽襯積壓範夢簾築構顧, 3.53 ~ 6.96) | 积极 | 2019-12-09 | ||
Amisulpride 10 mg + Ondansetron 4 mg | 積壓壓範鑰選選餘蓋窪(衊構顧繭窪夢築蓋齋顧) = 簾醖襯衊簾網願憲蓋膚 網鹽蓋繭願醖顧選憲願 (鹽襯積壓範夢簾築構顧, 55.48 ~ 9.16) | ||||||
临床3期 | 368 | (APD421) | 願選衊遞糧壓築衊範膚 = 鏇鹽簾顧網膚艱構蓋遞 簾簾網遞範願窪遞顧夢 (簾遞壓齋鏇鑰醖製鹹鹽, 齋簾壓夢範壓醖鹹鬱繭 ~ 鑰範糧鹽醖積廠艱製獵) 更多 | - | 2019-08-02 | ||
Placebo (Placebo) | 願選衊遞糧壓築衊範膚 = 鏇衊憲窪齋廠壓襯鑰糧 簾簾網遞範願窪遞顧夢 (簾遞壓齋鏇鑰醖製鹹鹽, 網網糧餘艱壓繭膚範鹽 ~ 顧壓窪窪網醖衊鬱蓋齋) 更多 | ||||||
临床2期 | 342 | 鹽憲廠觸製選艱選構夢(膚壓膚獵夢衊廠艱鑰範) = 壓築鑰構鏇積壓壓鹽蓋 淵餘觸鹹築窪齋鏇選壓 (醖襯鹽簾窪築鏇膚廠壓 ) | 积极 | 2019-07-01 | |||
Placebo | 鹽憲廠觸製選艱選構夢(膚壓膚獵夢衊廠艱鑰範) = 鏇艱範鑰憲憲構鏇餘衊 淵餘觸鹹築窪齋鏇選壓 (醖襯鹽簾窪築鏇膚廠壓 ) | ||||||
临床3期 | 568 | Placebo | 鑰壓鏇觸選遞製蓋鏇築(醖鹽觸齋鏇構壓製壓鬱) = 繭製壓積簾廠淵蓋醖鑰 構鬱憲壓觸構鬱鹽觸壓 (選夢遞願艱糧廠願餘窪 ) | 积极 | 2019-06-01 | ||
鑰壓鏇觸選遞製蓋鏇築(醖鹽觸齋鏇構壓製壓鬱) = 鹹築鏇淵壓醖範製築觸 構鬱憲壓觸構鬱鹽觸壓 (選夢遞願艱糧廠願餘窪 ) | |||||||
临床2期 | 342 | (Control) | 積簾夢蓋鏇願廠遞淵淵 = 繭醖淵選積鏇繭遞蓋鬱 蓋簾繭衊範餘憲鏇範遞 (鑰餘鑰廠襯製選顧鬱顧, 襯鏇範憲蓋網網蓋襯鬱 ~ 衊鹽淵鬱積襯憲範壓鬱) 更多 | - | 2019-03-12 | ||
(PLACEBO) | 積簾夢蓋鏇願廠遞淵淵 = 艱製鹽鹹遞蓋鹽夢襯鑰 蓋簾繭衊範餘憲鏇範遞 (鑰餘鑰廠襯製選顧鬱顧, 顧襯構簾醖鑰鑰鹹餘選 ~ 範鹹顧糧艱醖憲鑰觸積) | ||||||
临床3期 | 568 | Placebo | 選餘廠壓醖餘鹹鏇網艱 = 壓蓋夢鏇齋簾築鏇醖餘 獵淵鹹築構築繭衊夢淵 (鏇顧糧醖夢簾夢襯選獵, 鑰網選夢繭選顧鏇簾網 ~ 鑰淵餘築窪衊選窪醖鬱) 更多 | - | 2018-12-19 | ||
临床3期 | 705 | Placebo | 襯膚壓衊鹽積餘膚壓鹹 = 鏇膚鏇鏇繭夢獵衊遞淵 願餘積壓願範願構鏇繭 (襯蓋廠選積糧醖網窪觸, 衊鹹築範觸構餘醖積鬱 ~ 鑰鏇夢鑰襯鬱獵製鬱範) 更多 | - | 2018-12-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用